Clinical trials: Coronavirus Infection
Pneumonitis, SARS-CoV Infection
GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)
This clinical trial will evaluate the safety, tolerability and efficacy of GLS-1027 in the prevention of severe pneumonitis caused by SARS-CoV-2 infection
- Trial name
- NCT04590547
- Testing
- GLS-1027
- Where
- 17 sites in United States, Bulgaria and 3 more
- Volunteers
- 132 people
- Sponsor
- GeneOne Life Science, Inc.
SARS-CoV-2 Infection
Study of a Live rNDV Based Vaccine Against COVID-19
This is a Phase 1, open-label, non-randomized, dose-escalation study using three doses and two schemes of administration of a recombinant vaccine against SARS-CoV-2 based on a viral vector (Newcastle Disease virus) in 90 healthy…
- Trial name
- NCT04871737
- Testing
- Recombinant NDV Vectored Vaccine for SARS-CoV-2
- Where
- Mexico
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Laboratorio Avi-Mex, S.A. de C.V.
Influenza Type A, Influenza Type B
Clinical Feasibility of the BinaxNOW™ COVID-19/Flu A&B Combo in the Southern Hemisphere
The study is designed as a clinical feasibility, to investigate the positive and negative percent agreement (PPA and NPA) of the BinaxNOW™ COVID-19/Flu A\&B Combo against a highly sensitive PCR method(s) in symptomatic patients…
- Conditions
- Influenza Type A, Influenza Type B, COVID-19
- Trial name
- NCT06928129
- Testing
- BinaxNOW™ COVID-19/Flu A&B Combo Self-Test
- Volunteers
- 700 people
- Sponsor
- Abbott Rapid Dx
COVID-19
Study on Determine the Utilisation and Clinical Outcomes of Evusheld in COVID-19 PrEP in China
Evusheld(AZD7442) is a combination of 2 human long-acting antibodies, which was selected for maximal potency and demonstrated synergistic neutralization of SARS-CoV-2 in vitro.
- Trial name
- CLEAR (NCT05917951)
- Where
- China
- Volunteers
- 248 people
- Sponsor
- AstraZeneca
SARS-CoV-2, Covid19
Clinical Evaluation of a Point-of-Care (POC), COVID-19 Rapid Antigen Test (CoviDx™)
Prospective study that will evaluate the clinical agreement of the CoviDx™ Rapid Antigen test compared to SARS-CoV-2 RT-PCR.
- Trial name
- CoviDx (NCT04750629)
- Testing
- POC CoviDx™ Rapid Antigen Test
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Lumos Diagnostics
COVID-19
Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above
This is a randomized, double blind, positive controlled study to evaluate the safety and immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in population aged 18 years old and above who have been vaccinated with…
- Trial name
- COVID-19 (NCT05374954)
- Testing
- Omicron COVID-19 Vaccine (Vero Cell), Inactivated, COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- 10 sites in China
- Volunteers
- 4,200 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
COVID-19 Pulmonary Complications, COVID-19
Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
The primary objective of this study was to evaluate if the addition of zanubrutinib to supportive care increases the respiratory failure-free survival rate at Day 28 in participants hospitalized for Corona Virus Disease 2019…
- Trial name
- NCT04382586
- Testing
- Zanubrutinib, Supportive Care
- Where
- 10 sites in United States
- Volunteers
- 63 people
- Sponsor
- BeiGene
COVID-19, SARS-CoV-2 Infection
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.
The objective of this study is to evaluate the safety, tolerability, and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with inactivated COVID-19 vaccine.
- Trial name
- NCT05043285
- Testing
- SCTV01C
- Where
- United Arab Emirates
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Covid19
Study to Evaluate Efficacy and Safety of "VIRACIDE" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)
This is a double blind randomized placebo controlled study will be conducted on 124 subjects, 50 years and older with mild or asymptomatic COVID-19.
- Trial name
- NCT04596085
- Testing
- Investigational Product - ViraCide
- Where
- 2 sites in India
- Volunteers
- 118 people
- Sponsor
- The Herb, Inc
Thrombopenia, Covid19
COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients
This is a multicenter, open-label, single cohort study of patients with confirmed COVID-19 syndrome who based on clinical judgment require care in an intensive care unit, regardless of whether or not mechanical ventilation is in…
- Trial name
- NCT05040776
- Testing
- EP-7041 Injection
- Where
- United States
- Sponsor
- eXIthera Pharmaceuticals
COVID-19
[14C] Study to Investigate the Mass Balance and Biotransformation of WPV01 in Healthy Adult Chinese Male Participants
This is a single-center, non-randomized, open-label, single-dose, Phase I clinical study to evaluate the mass balance and biotransformation, safety and tolerability of WPV01 in healthy adult chinese male participants following a…
- Trial name
- NCT07080658
- Testing
- [14C]-WPV01
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
SARS-CoV-2 Infection
A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults
The primary objectives of this open-label trial were to evaluate the safety and pharmacokinetics (PK) of Anti-SARS-CoV-2 Immunoglobulin (Human) Investigational Product (COVID-HIG) administered intramuscularly (IM), subcutaneously…
- Trial name
- NCT05142306
- Testing
- COVID-HIG
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Covid-19
Exploratory Study to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers
The aim of this study is to explore potential for reduction of incidence and/or morbidity of SARS-CoV-2 infection in healthcare personnel. The study will include a comparison between placebo and RUTI® vaccine in a 2:1 design.
- Trial name
- NCT04903184
- Testing
- RUTI® vaccine
- Where
- 6 sites in Argentina
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- RUTI Immunotherapeutics S.L.
COVID 19 Disease
Tafenoquine in Patients With Mild to Moderate COVID-19
A clinical study to assess the efficacy and safety of oral tafenoquine compared to placebo in patients with mild to moderate COVID 19 disease.
- Trial name
- NCT04533347
- Testing
- Tafenoquine Oral Tablet
- Where
- 10 sites in United States
- Volunteers
- 86 people
- Sponsor
- 60 Degrees Pharmaceuticals LLC
COVID-19
A Study to Determine the Tolerability of Intranasal LMN-301
LMN-301 is to prevent infection by severe acute respiratory syndrome-corona virus (SARS-CoV-2) (the virus causing coronavirus disease of 2019 (COVID-19) in uninfected individuals.
- Trial name
- NCT06030414
- Testing
- LMN-301
- Where
- Australia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Lumen Bioscience, Inc.
Covid19, Corona Virus Infection
Expanded Access to Zofin for Patients With COVID-19
This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider…
- Conditions
- Covid19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT04657406
- Testing
- Zofin
- Sponsor
- ZEO ScientifiX, Inc.
COVID-19
Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients
The purpose of this study is to evaluate the safety and tolerability of single ascending IV dose administrations of GIGA-2050 in patients hospitalized with COVID-19.
- Trial name
- NCT04883138
- Testing
- GIGA-2050
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- GigaGen, Inc.
Coronavirus Infection
Clinical Evaluation of Cordio Application in Adult COVID-19 Virus Positive Patients
Study on adult patients positive to COVID-19 virus. After signing informed consent and undergoing screening assessments, eligible patients will record few times a day several pre-defined sentences to the Cordio App installed in a…
- Trial name
- NCT04325048
- Testing
- Cordio App
- Where
- Israel
- Volunteers
- 42 people
- Sponsor
- Cordio Medical
COVID-19 Pandemic
Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity
A Clinical Study to Evaluate the Safety and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of…
- Trial name
- COVID-19 (NCT05239832)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Covid19
Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients
The current study will investigate the tolerability and efficacy of inhaled Carragelose® versus saline in hospitalized COVID-19 patients.
- Trial name
- NCT04793984
- Testing
- Carragelose, NaCl
- Where
- Austria
- Volunteers
- 14 people
- Sponsor
- Marinomed Biotech AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.